Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 7/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 3/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 3/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23655558 | 0.94 | CYP2C9 (0.76) | CYP2C9CYP2C19CYP3A4EPHX2PDE2A | |
| SCHEMBL17876649 | 0.93 | CYP2C9 (0.85) | CYP2C9CYP2C19CYP3A4EPHX2SCN9A | |
| SCHEMBL17876676 | 0.92 | CYP2C9 (0.83) | CYP2C9CYP2C19CYP3A4EPHX2PDE2A | |
| SCHEMBL12295258 | 0.92 | CYP2C9 (1.00) | CYP2C9CYP2C19CYP3A4EPHX2SCN9A | |
| SCHEMBL17876669 | 0.92 | CYP2C9 (0.84) | CYP2C9CYP2C19CYP3A4EPHX2SCN9A | |
| SCHEMBL17876660 | 0.92 | CYP2C9 (0.84) | CYP2C9CYP2C19CYP3A4EPHX2SCN9A | |
| SCHEMBL17876721 | 0.92 | CYP2C9 (0.84) | CYP2C9CYP2C19CYP3A4EPHX2SCN9A | |
| SCHEMBL23609459 | 0.92 | CYP2C9 (0.72) | CYP2C9CYP2C19CYP3A4EPHX2PDE2A | |
| SCHEMBL17876648 | 0.91 | CYP2C9 (0.72) | CYP2C9CYP2C19CYP3A4KDM4EPKM | |
| SCHEMBL17876473 | 0.90 | CYP2C9 (0.71) | CYP2C9CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220235047-A1 | A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE | SHIONOGI & CO., LTD. (JP) | 2022-07-28 | — | — | US | disclosed |
| EP-3027615-B1 | ANTI-INFECTIVE COMPOUNDS | PASTEUR INSTITUT KOREA (KR) | 2021-07-21 | — | — | EP | disclosed |
| US-20160185774-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2016-06-30 | — | — | US | disclosed |
| US-20160185774-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235047-A1 | A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE | CYC1, MT-CO1, ABCB11 | CYP2C9 286/4885CYP2C19 273/4885CYP3A4 222/4885 |
| US-20160185774-A1 | Anti-Infective Compounds | RABGGTB, ELANE, SERPINB1 | CYP2C9 4235/4885CYP2C19 4181/4885CYP3A4 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.